grant

Implementation of DPYD gene sequencing as an adaptation of pharmacogenetic screening to prevent severe toxicity during cancer treatment with fluoropyrimidine chemotherapy

Organization DARTMOUTH COLLEGELocation HANOVER, UNITED STATESPosted 8 Aug 2025Deadline 31 May 2030
NIHUS FederalResearch GrantFY20255-FU5-Fluracil5FUAdverse ExperienceAdverse drug eventAdverse eventAsianAsian groupAsian individualAsian peopleAsian populationAsiansAssayAssess implementationBioassayBiological AssayBiomedical ResearchBlackBlack PopulationsBlack groupBlack individualBlack peopleBlack raceBlacksBloodBlood PlasmaBlood Reticuloendothelial SystemBreast CancerCancer CenterCancer TreatmentCessation of lifeCharacteristicsClinicalConsensusDPYD geneDataDeathDiagnosticDihydropyrimidine DehydrogenaseDihydrothymine Dehydrogenase (NADP)DoseDrug usageDrugsEffectivenessEligibilityEligibility DeterminationEquityEuropeEuropeanEvidence based practiceFluoro UracilFluorouracilFluoruracilFluouracilGene variantGenesGenotypeHealth Care ProvidersHealth PersonnelHispanicHispanic PopulationsHispanic groupHispanic individualHispanic peopleHispanicsHybridsImplementation assessmentImplementation readinessIncidenceIndividuals from minorityIndividuals of minorityKnowledgeLaboratoriesLearningMalignant Breast NeoplasmMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant Pancreatic NeoplasmMalignant neoplasm of pancreasMeasurementMedicationMethodsMinority GroupsMinority PeopleMinority PopulationMinority individualModelingMonitorOncologistPancreas CancerPancreatic CancerPatientsPersonsPharmaceutical PreparationsPharmacistsPharmacogeneticsPhenotypePlasmaPlasma SerumPoliciesPopulationProtocol ScreeningResearchResearch SpecimenReticuloendothelial System, Serum, PlasmaRiskRoleSafetyScreening ResultSerious Adverse EventSevere Adverse EventSpecimenTestingTimeToxic effectToxicitiesToxicity due to chemotherapyUncertaintyUnderrepresented GroupsUnderrepresented PopulationsUnited StatesUracilVariantVariationWorkXelodaallelic variantanti-cancer therapyassess effectivenesscancer carecancer therapycancer-directed therapycapecitabinecare deliverychemotherapychemotherapy toxicityclinical decision-makingclinical implementationcolorectal cancer therapycolorectal cancer treatmentdetermine effectivenessdoubtdrug usedrug/agenteffectiveness assessmenteffectiveness evaluationevaluate effectivenessevaluate implementationevaluation of implementationevidence baseexamine effectivenessexperiencefacilitators to implementationfluoropyrimidinegenetic variantgenomic varianthealth care personnelhealth care workerhealth providerhealth workforceimplementation determinantsimplementation effortsimplementation evaluationimplementation facilitatorsimplementation factorsimplementation outcomesimplementation scienceimplementation strategyimprovedmalignant breast tumormedical personnelnew approachesnovel approachesnovel strategiesnovel strategypancreatic malignancypatient populationpatient safetypatient screeningpractice settingpreventpreventingprospectivescreeningscreening uptakescreeningsserious adverse experienceserious adverse reactionside effectsocial rolestrategies for implementationtooltreatment providerunder representation of groupsunder represented groupsunder represented peopleunder represented populationsunderrepresentation of groupsunderrepresented people
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Abstract/project summary
The fluoropyrimidine chemotherapies 5-fluorouracil and capecitabine are essential agents for the treatment of

colorectal, breast, and pancreatic cancer; however, these agents are also responsible for hundreds of fatal

adverse drug events in the United States (US) each year. Dihydropyrimidine dehydrogenase (DPD) deficiency…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Implementation of DPYD gene sequencing as an adaptation of pharmacogenetic screening to prevent severe toxicity during c | Dev Procure